Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
10x Genomics
TXG
10x Genomics
US Funding Cuts And Global Pressures Will Hamper Progress
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 13 Analysts
Published
07 Aug 25
Updated
07 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$9.00
58.9% overvalued
intrinsic discount
07 Aug
US$14.30
Loading
1Y
-39.1%
7D
7.0%
Author's Valuation
US$9.0
58.9% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$9.0
58.9% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-504m
641m
2017
2019
2021
2023
2025
2027
2028
Revenue US$641.4m
Earnings US$91.3m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
3.03%
Life Sciences revenue growth rate
0.33%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
7.23%
Calculation
US$91.28m
Earnings '28
x
15.92x
PE Ratio '28
=
US$1.45b
Market Cap '28
US$1.45b
Market Cap '28
/
131.41m
No. shares '28
=
US$11.05
Share Price '28
US$11.05
Share Price '28
Discounted to 2025 @ 7.21% p.a.
=
US$8.97
Fair Value '25